Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. Aging Knowl. Environ., 17 March 2004
Vol. 2004, Issue 11, p. pe12
[DOI: 10.1126/sageke.2004.11.pe12]


Exploiting Proteomics in the Discovery of Drugs That Target Mitochondrial Oxidative Damage

Bradford W. Gibson

The author is at the Buck Institute for Age Research, Novato, CA 94945, USA and in the Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143, USA. E-mail: bgibson{at}

Key Words: mass spectrometry • neurodegenerative disease • mitochondrial complex I • oxidative stress • posttranslational modifications

Abstract: To understand how oxidative stress contributes to aging and age-related diseases and to better evaluate the therapeutic effect of antioxidant drugs, it would be highly desirable to have a comprehensive and detailed readout of the types of oxidative damage that occur to proteins at a global or proteome level. In this Perspective, I examine how proteomics, defined here as the science of examining all proteins in an organelle, cell, or tissue in the context of biological phenomena, can be used to provide molecular details of mitochondrial protein oxidative damage. Specifically, I discuss approaches that combine knowledge of the mitochondrial proteome with newer mass spectrometry-based techniques that are capable of identifying proteins and sites of oxidative modification in a high-throughput manner.

Citation: B. W. Gibson, Exploiting Proteomics in the Discovery of Drugs That Target Mitochondrial Oxidative Damage. Sci. Aging Knowl. Environ. 2004 (11), pe12 (2004).

Read the Full Text

To Advertise     Find Products

Science of Aging Knowledge Environment. ISSN 1539-6150